nodes	percent_of_prediction	percent_of_DWPC	metapath
Procainamide—BCHE—Cisplatin—urinary bladder cancer	0.0381	0.473	CbGbCtD
Procainamide—SLC22A2—Cisplatin—urinary bladder cancer	0.0364	0.451	CbGbCtD
Procainamide—SCN7A—prostate gland—urinary bladder cancer	0.013	0.0503	CbGeAlD
Procainamide—SCN9A—prostate gland—urinary bladder cancer	0.0102	0.0394	CbGeAlD
Procainamide—DNMT1—prostate gland—urinary bladder cancer	0.00998	0.0387	CbGeAlD
Procainamide—SCN4A—prostate gland—urinary bladder cancer	0.00907	0.0352	CbGeAlD
Procainamide—DNMT1—seminal vesicle—urinary bladder cancer	0.00844	0.0327	CbGeAlD
Procainamide—ACHE—prostate gland—urinary bladder cancer	0.0081	0.0314	CbGeAlD
Procainamide—CYP2D6—urine—urinary bladder cancer	0.00735	0.0285	CbGeAlD
Procainamide—DNMT1—epithelium—urinary bladder cancer	0.00733	0.0284	CbGeAlD
Procainamide—SCN7A—female reproductive system—urinary bladder cancer	0.00709	0.0275	CbGeAlD
Procainamide—SCN3A—prostate gland—urinary bladder cancer	0.00706	0.0274	CbGeAlD
Procainamide—DNMT1—urethra—urinary bladder cancer	0.00668	0.0259	CbGeAlD
Procainamide—SCN4A—renal system—urinary bladder cancer	0.00618	0.024	CbGeAlD
Procainamide—SLC22A4—prostate gland—urinary bladder cancer	0.00618	0.024	CbGeAlD
Procainamide—CYP2D6—Doxorubicin—urinary bladder cancer	0.00611	0.0758	CbGbCtD
Procainamide—CHRM2—prostate gland—urinary bladder cancer	0.00599	0.0232	CbGeAlD
Procainamide—SLC22A2—renal system—urinary bladder cancer	0.00568	0.022	CbGeAlD
Procainamide—SLC22A3—prostate gland—urinary bladder cancer	0.00562	0.0218	CbGeAlD
Procainamide—DNMT1—female reproductive system—urinary bladder cancer	0.00545	0.0211	CbGeAlD
Procainamide—SLC22A4—seminal vesicle—urinary bladder cancer	0.00523	0.0203	CbGeAlD
Procainamide—DNMT1—vagina—urinary bladder cancer	0.00492	0.0191	CbGeAlD
Procainamide—SCN3A—renal system—urinary bladder cancer	0.00481	0.0186	CbGeAlD
Procainamide—SLC22A3—seminal vesicle—urinary bladder cancer	0.00476	0.0184	CbGeAlD
Procainamide—SLC22A4—renal system—urinary bladder cancer	0.00421	0.0163	CbGeAlD
Procainamide—SCN7A—lymph node—urinary bladder cancer	0.00415	0.0161	CbGeAlD
Procainamide—SLC22A5—prostate gland—urinary bladder cancer	0.00409	0.0159	CbGeAlD
Procainamide—SLC22A1—renal system—urinary bladder cancer	0.00401	0.0156	CbGeAlD
Procainamide—BCHE—prostate gland—urinary bladder cancer	0.00398	0.0154	CbGeAlD
Procainamide—SLC22A3—smooth muscle tissue—urinary bladder cancer	0.00398	0.0154	CbGeAlD
Procainamide—SCN2A—vagina—urinary bladder cancer	0.00396	0.0154	CbGeAlD
Procainamide—SCN3A—female reproductive system—urinary bladder cancer	0.00385	0.0149	CbGeAlD
Procainamide—SLC22A3—renal system—urinary bladder cancer	0.00383	0.0149	CbGeAlD
Procainamide—SLC22A3—urethra—urinary bladder cancer	0.00377	0.0146	CbGeAlD
Procainamide—SCN3A—vagina—urinary bladder cancer	0.00348	0.0135	CbGeAlD
Procainamide—SCN5A—vagina—urinary bladder cancer	0.00347	0.0135	CbGeAlD
Procainamide—SLC22A5—seminal vesicle—urinary bladder cancer	0.00346	0.0134	CbGeAlD
Procainamide—SLC22A4—female reproductive system—urinary bladder cancer	0.00337	0.0131	CbGeAlD
Procainamide—BCHE—seminal vesicle—urinary bladder cancer	0.00337	0.0131	CbGeAlD
Procainamide—SCN9A—lymph node—urinary bladder cancer	0.00325	0.0126	CbGeAlD
Procainamide—DNMT1—lymph node—urinary bladder cancer	0.00319	0.0123	CbGeAlD
Procainamide—SLC22A3—female reproductive system—urinary bladder cancer	0.00307	0.0119	CbGeAlD
Procainamide—SLC22A4—vagina—urinary bladder cancer	0.00305	0.0118	CbGeAlD
Procainamide—SLC22A1—vagina—urinary bladder cancer	0.00291	0.0113	CbGeAlD
Procainamide—BCHE—smooth muscle tissue—urinary bladder cancer	0.00282	0.0109	CbGeAlD
Procainamide—SLC22A5—renal system—urinary bladder cancer	0.00279	0.0108	CbGeAlD
Procainamide—SLC22A3—vagina—urinary bladder cancer	0.00278	0.0108	CbGeAlD
Procainamide—SLC22A5—urethra—urinary bladder cancer	0.00274	0.0106	CbGeAlD
Procainamide—ACHE—lymph node—urinary bladder cancer	0.00259	0.01	CbGeAlD
Procainamide—SCN10A—lymph node—urinary bladder cancer	0.00247	0.00959	CbGeAlD
Procainamide—SCN3A—lymph node—urinary bladder cancer	0.00225	0.00874	CbGeAlD
Procainamide—SLC22A5—female reproductive system—urinary bladder cancer	0.00223	0.00865	CbGeAlD
Procainamide—BCHE—female reproductive system—urinary bladder cancer	0.00217	0.00843	CbGeAlD
Procainamide—SLC22A5—vagina—urinary bladder cancer	0.00202	0.00783	CbGeAlD
Procainamide—SLC22A4—lymph node—urinary bladder cancer	0.00197	0.00765	CbGeAlD
Procainamide—BCHE—vagina—urinary bladder cancer	0.00197	0.00762	CbGeAlD
Procainamide—Cardiac failure—Etoposide—urinary bladder cancer	0.00196	0.00462	CcSEcCtD
Procainamide—Hepatomegaly—Doxorubicin—urinary bladder cancer	0.00193	0.00455	CcSEcCtD
Procainamide—Pleural effusion—Epirubicin—urinary bladder cancer	0.00193	0.00455	CcSEcCtD
Procainamide—Agranulocytosis—Thiotepa—urinary bladder cancer	0.00191	0.00452	CcSEcCtD
Procainamide—Eosinophilia—Fluorouracil—urinary bladder cancer	0.00188	0.00445	CcSEcCtD
Procainamide—Asthenia—Mitomycin—urinary bladder cancer	0.00187	0.0044	CcSEcCtD
Procainamide—Hallucination—Thiotepa—urinary bladder cancer	0.00183	0.00432	CcSEcCtD
Procainamide—Cardiac arrest—Etoposide—urinary bladder cancer	0.00182	0.00429	CcSEcCtD
Procainamide—Neutropenia—Gemcitabine—urinary bladder cancer	0.00181	0.00427	CcSEcCtD
Procainamide—CYP2D6—renal system—urinary bladder cancer	0.0018	0.00697	CbGeAlD
Procainamide—SLC22A3—lymph node—urinary bladder cancer	0.0018	0.00696	CbGeAlD
Procainamide—Pleural effusion—Doxorubicin—urinary bladder cancer	0.00178	0.00421	CcSEcCtD
Procainamide—Diarrhoea—Mitomycin—urinary bladder cancer	0.00178	0.0042	CcSEcCtD
Procainamide—Abdominal discomfort—Cisplatin—urinary bladder cancer	0.00173	0.00408	CcSEcCtD
Procainamide—Dizziness—Mitomycin—urinary bladder cancer	0.00172	0.00406	CcSEcCtD
Procainamide—Oliguria—Methotrexate—urinary bladder cancer	0.00171	0.00404	CcSEcCtD
Procainamide—Cardiac disorder—Thiotepa—urinary bladder cancer	0.00171	0.00403	CcSEcCtD
Procainamide—Renal failure—Gemcitabine—urinary bladder cancer	0.00169	0.004	CcSEcCtD
Procainamide—Hepatic enzyme increased—Methotrexate—urinary bladder cancer	0.00167	0.00394	CcSEcCtD
Procainamide—Vomiting—Mitomycin—urinary bladder cancer	0.00165	0.0039	CcSEcCtD
Procainamide—Chills—Thiotepa—urinary bladder cancer	0.00165	0.0039	CcSEcCtD
Procainamide—Vasculitis—Methotrexate—urinary bladder cancer	0.00162	0.00381	CcSEcCtD
Procainamide—Agranulocytosis—Gemcitabine—urinary bladder cancer	0.00161	0.0038	CcSEcCtD
Procainamide—Oliguria—Epirubicin—urinary bladder cancer	0.0016	0.00378	CcSEcCtD
Procainamide—Agranulocytosis—Fluorouracil—urinary bladder cancer	0.00158	0.00374	CcSEcCtD
Procainamide—Renal failure—Cisplatin—urinary bladder cancer	0.00158	0.00373	CcSEcCtD
Procainamide—Neutropenia—Etoposide—urinary bladder cancer	0.00154	0.00365	CcSEcCtD
Procainamide—Nausea—Mitomycin—urinary bladder cancer	0.00154	0.00365	CcSEcCtD
Procainamide—Oliguria—Doxorubicin—urinary bladder cancer	0.00148	0.0035	CcSEcCtD
Procainamide—Ventricular tachycardia—Epirubicin—urinary bladder cancer	0.00148	0.00348	CcSEcCtD
Procainamide—Bradycardia—Cisplatin—urinary bladder cancer	0.00147	0.00347	CcSEcCtD
Procainamide—Renal failure—Etoposide—urinary bladder cancer	0.00145	0.00342	CcSEcCtD
Procainamide—CYP2D6—female reproductive system—urinary bladder cancer	0.00144	0.00558	CbGeAlD
Procainamide—Cardiac disorder—Gemcitabine—urinary bladder cancer	0.00144	0.00339	CcSEcCtD
Procainamide—Chills—Gemcitabine—urinary bladder cancer	0.00139	0.00328	CcSEcCtD
Procainamide—Convulsion—Thiotepa—urinary bladder cancer	0.00139	0.00328	CcSEcCtD
Procainamide—Agranulocytosis—Etoposide—urinary bladder cancer	0.00137	0.00324	CcSEcCtD
Procainamide—Ventricular tachycardia—Doxorubicin—urinary bladder cancer	0.00137	0.00322	CcSEcCtD
Procainamide—Arthralgia—Thiotepa—urinary bladder cancer	0.00136	0.00322	CcSEcCtD
Procainamide—Myalgia—Thiotepa—urinary bladder cancer	0.00136	0.00322	CcSEcCtD
Procainamide—Rash maculo-papular—Epirubicin—urinary bladder cancer	0.00134	0.00317	CcSEcCtD
Procainamide—Cardiac disorder—Cisplatin—urinary bladder cancer	0.00134	0.00316	CcSEcCtD
Procainamide—Flushing—Cisplatin—urinary bladder cancer	0.00134	0.00316	CcSEcCtD
Procainamide—Confusional state—Thiotepa—urinary bladder cancer	0.00132	0.00311	CcSEcCtD
Procainamide—SLC22A5—lymph node—urinary bladder cancer	0.00131	0.00506	CbGeAlD
Procainamide—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.00128	0.00302	CcSEcCtD
Procainamide—Hepatic failure—Methotrexate—urinary bladder cancer	0.00127	0.00301	CcSEcCtD
Procainamide—BCHE—lymph node—urinary bladder cancer	0.00127	0.00493	CbGeAlD
Procainamide—Ill-defined disorder—Gemcitabine—urinary bladder cancer	0.00125	0.00295	CcSEcCtD
Procainamide—Anorexia—Thiotepa—urinary bladder cancer	0.00125	0.00294	CcSEcCtD
Procainamide—Rash maculo-papular—Doxorubicin—urinary bladder cancer	0.00124	0.00293	CcSEcCtD
Procainamide—Cardiac disorder—Etoposide—urinary bladder cancer	0.00123	0.0029	CcSEcCtD
Procainamide—Flushing—Etoposide—urinary bladder cancer	0.00123	0.0029	CcSEcCtD
Procainamide—Malaise—Gemcitabine—urinary bladder cancer	0.00122	0.00287	CcSEcCtD
Procainamide—Hepatic failure—Epirubicin—urinary bladder cancer	0.00119	0.00281	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.00119	0.00281	CcSEcCtD
Procainamide—Chills—Etoposide—urinary bladder cancer	0.00119	0.0028	CcSEcCtD
Procainamide—Lethargy—Methotrexate—urinary bladder cancer	0.00117	0.00276	CcSEcCtD
Procainamide—Ill-defined disorder—Cisplatin—urinary bladder cancer	0.00117	0.00275	CcSEcCtD
Procainamide—Convulsion—Fluorouracil—urinary bladder cancer	0.00115	0.00271	CcSEcCtD
Procainamide—Myalgia—Gemcitabine—urinary bladder cancer	0.00115	0.00271	CcSEcCtD
Procainamide—Arthralgia—Gemcitabine—urinary bladder cancer	0.00115	0.00271	CcSEcCtD
Procainamide—Decreased appetite—Thiotepa—urinary bladder cancer	0.00114	0.00268	CcSEcCtD
Procainamide—Discomfort—Gemcitabine—urinary bladder cancer	0.00113	0.00268	CcSEcCtD
Procainamide—Malaise—Cisplatin—urinary bladder cancer	0.00113	0.00267	CcSEcCtD
Procainamide—Myalgia—Fluorouracil—urinary bladder cancer	0.00113	0.00266	CcSEcCtD
Procainamide—Dysgeusia—Etoposide—urinary bladder cancer	0.00113	0.00266	CcSEcCtD
Procainamide—Renal impairment—Epirubicin—urinary bladder cancer	0.00113	0.00266	CcSEcCtD
Procainamide—Discomfort—Fluorouracil—urinary bladder cancer	0.00111	0.00263	CcSEcCtD
Procainamide—Hepatic failure—Doxorubicin—urinary bladder cancer	0.0011	0.0026	CcSEcCtD
Procainamide—Cardiac failure—Epirubicin—urinary bladder cancer	0.0011	0.00259	CcSEcCtD
Procainamide—Lethargy—Epirubicin—urinary bladder cancer	0.00109	0.00258	CcSEcCtD
Procainamide—Confusional state—Fluorouracil—urinary bladder cancer	0.00109	0.00257	CcSEcCtD
Procainamide—Convulsion—Cisplatin—urinary bladder cancer	0.00109	0.00257	CcSEcCtD
Procainamide—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00108	0.00254	CcSEcCtD
Procainamide—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.00108	0.00254	CcSEcCtD
Procainamide—Myalgia—Cisplatin—urinary bladder cancer	0.00107	0.00253	CcSEcCtD
Procainamide—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00107	0.00252	CcSEcCtD
Procainamide—Ill-defined disorder—Etoposide—urinary bladder cancer	0.00107	0.00252	CcSEcCtD
Procainamide—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.00106	0.0025	CcSEcCtD
Procainamide—Discomfort—Cisplatin—urinary bladder cancer	0.00106	0.00249	CcSEcCtD
Procainamide—Anorexia—Gemcitabine—urinary bladder cancer	0.00105	0.00248	CcSEcCtD
Procainamide—Renal impairment—Doxorubicin—urinary bladder cancer	0.00104	0.00246	CcSEcCtD
Procainamide—Urticaria—Thiotepa—urinary bladder cancer	0.00104	0.00245	CcSEcCtD
Procainamide—Malaise—Etoposide—urinary bladder cancer	0.00104	0.00245	CcSEcCtD
Procainamide—Body temperature increased—Thiotepa—urinary bladder cancer	0.00103	0.00244	CcSEcCtD
Procainamide—Abdominal pain—Thiotepa—urinary bladder cancer	0.00103	0.00244	CcSEcCtD
Procainamide—Anorexia—Fluorouracil—urinary bladder cancer	0.00103	0.00243	CcSEcCtD
Procainamide—Hypotension—Gemcitabine—urinary bladder cancer	0.00103	0.00243	CcSEcCtD
Procainamide—Cardiac arrest—Epirubicin—urinary bladder cancer	0.00102	0.0024	CcSEcCtD
Procainamide—Cardiac failure—Doxorubicin—urinary bladder cancer	0.00102	0.0024	CcSEcCtD
Procainamide—Lethargy—Doxorubicin—urinary bladder cancer	0.00101	0.00239	CcSEcCtD
Procainamide—Hypotension—Fluorouracil—urinary bladder cancer	0.00101	0.00239	CcSEcCtD
Procainamide—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.001	0.00237	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.001	0.00237	CcSEcCtD
Procainamide—Convulsion—Etoposide—urinary bladder cancer	0.000997	0.00235	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000985	0.00233	CcSEcCtD
Procainamide—Eosinophilia—Methotrexate—urinary bladder cancer	0.000979	0.00231	CcSEcCtD
Procainamide—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.000978	0.00231	CcSEcCtD
Procainamide—Anorexia—Cisplatin—urinary bladder cancer	0.000977	0.00231	CcSEcCtD
Procainamide—Discomfort—Etoposide—urinary bladder cancer	0.000968	0.00229	CcSEcCtD
Procainamide—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000963	0.00227	CcSEcCtD
Procainamide—Hypotension—Cisplatin—urinary bladder cancer	0.000958	0.00226	CcSEcCtD
Procainamide—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000956	0.00226	CcSEcCtD
Procainamide—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000948	0.00224	CcSEcCtD
Procainamide—Confusional state—Etoposide—urinary bladder cancer	0.000947	0.00224	CcSEcCtD
Procainamide—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.000942	0.00223	CcSEcCtD
Procainamide—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00094	0.00222	CcSEcCtD
Procainamide—Asthenia—Thiotepa—urinary bladder cancer	0.000938	0.00221	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000934	0.00221	CcSEcCtD
Procainamide—Neutropenia—Methotrexate—urinary bladder cancer	0.000925	0.00218	CcSEcCtD
Procainamide—Pruritus—Thiotepa—urinary bladder cancer	0.000925	0.00218	CcSEcCtD
Procainamide—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000919	0.00217	CcSEcCtD
Procainamide—Eosinophilia—Epirubicin—urinary bladder cancer	0.000917	0.00216	CcSEcCtD
Procainamide—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000906	0.00214	CcSEcCtD
Procainamide—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.000905	0.00214	CcSEcCtD
Procainamide—Anorexia—Etoposide—urinary bladder cancer	0.000895	0.00211	CcSEcCtD
Procainamide—Diarrhoea—Thiotepa—urinary bladder cancer	0.000894	0.00211	CcSEcCtD
Procainamide—Decreased appetite—Cisplatin—urinary bladder cancer	0.000891	0.0021	CcSEcCtD
Procainamide—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000891	0.0021	CcSEcCtD
Procainamide—Depression—Methotrexate—urinary bladder cancer	0.000879	0.00208	CcSEcCtD
Procainamide—Hypotension—Etoposide—urinary bladder cancer	0.000877	0.00207	CcSEcCtD
Procainamide—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000869	0.00205	CcSEcCtD
Procainamide—Renal failure—Methotrexate—urinary bladder cancer	0.000867	0.00205	CcSEcCtD
Procainamide—Neutropenia—Epirubicin—urinary bladder cancer	0.000866	0.00204	CcSEcCtD
Procainamide—Dizziness—Thiotepa—urinary bladder cancer	0.000864	0.00204	CcSEcCtD
Procainamide—Urticaria—Fluorouracil—urinary bladder cancer	0.000859	0.00203	CcSEcCtD
Procainamide—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000855	0.00202	CcSEcCtD
Procainamide—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000848	0.002	CcSEcCtD
Procainamide—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000845	0.00199	CcSEcCtD
Procainamide—Vomiting—Thiotepa—urinary bladder cancer	0.000831	0.00196	CcSEcCtD
Procainamide—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000823	0.00194	CcSEcCtD
Procainamide—Decreased appetite—Etoposide—urinary bladder cancer	0.000816	0.00193	CcSEcCtD
Procainamide—Renal failure—Epirubicin—urinary bladder cancer	0.000811	0.00192	CcSEcCtD
Procainamide—Body temperature increased—Cisplatin—urinary bladder cancer	0.00081	0.00191	CcSEcCtD
Procainamide—Neutropenia—Doxorubicin—urinary bladder cancer	0.000801	0.00189	CcSEcCtD
Procainamide—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000797	0.00188	CcSEcCtD
Procainamide—Asthenia—Gemcitabine—urinary bladder cancer	0.000789	0.00186	CcSEcCtD
Procainamide—Pruritus—Gemcitabine—urinary bladder cancer	0.000778	0.00184	CcSEcCtD
Procainamide—Nausea—Thiotepa—urinary bladder cancer	0.000777	0.00183	CcSEcCtD
Procainamide—Feeling abnormal—Etoposide—urinary bladder cancer	0.000774	0.00183	CcSEcCtD
Procainamide—Agranulocytosis—Epirubicin—urinary bladder cancer	0.00077	0.00182	CcSEcCtD
Procainamide—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000768	0.00181	CcSEcCtD
Procainamide—Pruritus—Fluorouracil—urinary bladder cancer	0.000765	0.00181	CcSEcCtD
Procainamide—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000755	0.00178	CcSEcCtD
Procainamide—Bradycardia—Epirubicin—urinary bladder cancer	0.000754	0.00178	CcSEcCtD
Procainamide—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000752	0.00178	CcSEcCtD
Procainamide—Renal failure—Doxorubicin—urinary bladder cancer	0.000751	0.00177	CcSEcCtD
Procainamide—Urticaria—Etoposide—urinary bladder cancer	0.000746	0.00176	CcSEcCtD
Procainamide—Abdominal pain—Etoposide—urinary bladder cancer	0.000742	0.00175	CcSEcCtD
Procainamide—Body temperature increased—Etoposide—urinary bladder cancer	0.000742	0.00175	CcSEcCtD
Procainamide—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00074	0.00175	CcSEcCtD
Procainamide—Asthenia—Cisplatin—urinary bladder cancer	0.000735	0.00174	CcSEcCtD
Procainamide—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000735	0.00174	CcSEcCtD
Procainamide—Dizziness—Fluorouracil—urinary bladder cancer	0.000715	0.00169	CcSEcCtD
Procainamide—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000713	0.00168	CcSEcCtD
Procainamide—Chills—Methotrexate—urinary bladder cancer	0.00071	0.00168	CcSEcCtD
Procainamide—Diarrhoea—Cisplatin—urinary bladder cancer	0.000701	0.00166	CcSEcCtD
Procainamide—Vomiting—Gemcitabine—urinary bladder cancer	0.000699	0.00165	CcSEcCtD
Procainamide—Bradycardia—Doxorubicin—urinary bladder cancer	0.000698	0.00165	CcSEcCtD
Procainamide—Hypersensitivity—Etoposide—urinary bladder cancer	0.000692	0.00163	CcSEcCtD
Procainamide—Flushing—Epirubicin—urinary bladder cancer	0.000688	0.00162	CcSEcCtD
Procainamide—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000688	0.00162	CcSEcCtD
Procainamide—Vomiting—Fluorouracil—urinary bladder cancer	0.000687	0.00162	CcSEcCtD
Procainamide—Dysgeusia—Methotrexate—urinary bladder cancer	0.000675	0.00159	CcSEcCtD
Procainamide—Asthenia—Etoposide—urinary bladder cancer	0.000674	0.00159	CcSEcCtD
Procainamide—Chills—Epirubicin—urinary bladder cancer	0.000665	0.00157	CcSEcCtD
Procainamide—Pruritus—Etoposide—urinary bladder cancer	0.000664	0.00157	CcSEcCtD
Procainamide—Nausea—Gemcitabine—urinary bladder cancer	0.000653	0.00154	CcSEcCtD
Procainamide—Vomiting—Cisplatin—urinary bladder cancer	0.000652	0.00154	CcSEcCtD
Procainamide—Diarrhoea—Etoposide—urinary bladder cancer	0.000643	0.00152	CcSEcCtD
Procainamide—Nausea—Fluorouracil—urinary bladder cancer	0.000642	0.00152	CcSEcCtD
Procainamide—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000639	0.00151	CcSEcCtD
Procainamide—Flushing—Doxorubicin—urinary bladder cancer	0.000636	0.0015	CcSEcCtD
Procainamide—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000636	0.0015	CcSEcCtD
Procainamide—Dysgeusia—Epirubicin—urinary bladder cancer	0.000632	0.00149	CcSEcCtD
Procainamide—Malaise—Methotrexate—urinary bladder cancer	0.000622	0.00147	CcSEcCtD
Procainamide—Dizziness—Etoposide—urinary bladder cancer	0.000621	0.00147	CcSEcCtD
Procainamide—Chills—Doxorubicin—urinary bladder cancer	0.000615	0.00145	CcSEcCtD
Procainamide—Nausea—Cisplatin—urinary bladder cancer	0.000609	0.00144	CcSEcCtD
Procainamide—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000598	0.00141	CcSEcCtD
Procainamide—Convulsion—Methotrexate—urinary bladder cancer	0.000597	0.00141	CcSEcCtD
Procainamide—Vomiting—Etoposide—urinary bladder cancer	0.000597	0.00141	CcSEcCtD
Procainamide—Myalgia—Methotrexate—urinary bladder cancer	0.000587	0.00139	CcSEcCtD
Procainamide—Arthralgia—Methotrexate—urinary bladder cancer	0.000587	0.00139	CcSEcCtD
Procainamide—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000584	0.00138	CcSEcCtD
Procainamide—Malaise—Epirubicin—urinary bladder cancer	0.000582	0.00137	CcSEcCtD
Procainamide—Discomfort—Methotrexate—urinary bladder cancer	0.00058	0.00137	CcSEcCtD
Procainamide—Confusional state—Methotrexate—urinary bladder cancer	0.000567	0.00134	CcSEcCtD
Procainamide—Convulsion—Epirubicin—urinary bladder cancer	0.000559	0.00132	CcSEcCtD
Procainamide—Nausea—Etoposide—urinary bladder cancer	0.000558	0.00132	CcSEcCtD
Procainamide—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000554	0.00131	CcSEcCtD
Procainamide—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000551	0.0013	CcSEcCtD
Procainamide—Arthralgia—Epirubicin—urinary bladder cancer	0.000549	0.0013	CcSEcCtD
Procainamide—Myalgia—Epirubicin—urinary bladder cancer	0.000549	0.0013	CcSEcCtD
Procainamide—Discomfort—Epirubicin—urinary bladder cancer	0.000543	0.00128	CcSEcCtD
Procainamide—Malaise—Doxorubicin—urinary bladder cancer	0.000538	0.00127	CcSEcCtD
Procainamide—Anorexia—Methotrexate—urinary bladder cancer	0.000536	0.00127	CcSEcCtD
Procainamide—Confusional state—Epirubicin—urinary bladder cancer	0.000531	0.00125	CcSEcCtD
Procainamide—Hypotension—Methotrexate—urinary bladder cancer	0.000526	0.00124	CcSEcCtD
Procainamide—Shock—Epirubicin—urinary bladder cancer	0.000518	0.00122	CcSEcCtD
Procainamide—Convulsion—Doxorubicin—urinary bladder cancer	0.000517	0.00122	CcSEcCtD
Procainamide—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000515	0.00122	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000512	0.00121	CcSEcCtD
Procainamide—Arthralgia—Doxorubicin—urinary bladder cancer	0.000508	0.0012	CcSEcCtD
Procainamide—Myalgia—Doxorubicin—urinary bladder cancer	0.000508	0.0012	CcSEcCtD
Procainamide—Discomfort—Doxorubicin—urinary bladder cancer	0.000502	0.00119	CcSEcCtD
Procainamide—Anorexia—Epirubicin—urinary bladder cancer	0.000502	0.00118	CcSEcCtD
Procainamide—Hypotension—Epirubicin—urinary bladder cancer	0.000492	0.00116	CcSEcCtD
Procainamide—Confusional state—Doxorubicin—urinary bladder cancer	0.000491	0.00116	CcSEcCtD
Procainamide—Decreased appetite—Methotrexate—urinary bladder cancer	0.000489	0.00115	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00048	0.00113	CcSEcCtD
Procainamide—Shock—Doxorubicin—urinary bladder cancer	0.000479	0.00113	CcSEcCtD
Procainamide—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000477	0.00113	CcSEcCtD
Procainamide—Anorexia—Doxorubicin—urinary bladder cancer	0.000464	0.0011	CcSEcCtD
Procainamide—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000464	0.00109	CcSEcCtD
Procainamide—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.00046	0.00109	CcSEcCtD
Procainamide—Decreased appetite—Epirubicin—urinary bladder cancer	0.000458	0.00108	CcSEcCtD
Procainamide—Hypotension—Doxorubicin—urinary bladder cancer	0.000455	0.00107	CcSEcCtD
Procainamide—Urticaria—Methotrexate—urinary bladder cancer	0.000447	0.00106	CcSEcCtD
Procainamide—Abdominal pain—Methotrexate—urinary bladder cancer	0.000445	0.00105	CcSEcCtD
Procainamide—Body temperature increased—Methotrexate—urinary bladder cancer	0.000445	0.00105	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000444	0.00105	CcSEcCtD
Procainamide—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000434	0.00102	CcSEcCtD
Procainamide—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.00043	0.00102	CcSEcCtD
Procainamide—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000423	0.001	CcSEcCtD
Procainamide—Urticaria—Epirubicin—urinary bladder cancer	0.000418	0.000988	CcSEcCtD
Procainamide—Abdominal pain—Epirubicin—urinary bladder cancer	0.000416	0.000983	CcSEcCtD
Procainamide—Body temperature increased—Epirubicin—urinary bladder cancer	0.000416	0.000983	CcSEcCtD
Procainamide—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000414	0.000979	CcSEcCtD
Procainamide—Asthenia—Methotrexate—urinary bladder cancer	0.000404	0.000953	CcSEcCtD
Procainamide—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000401	0.000948	CcSEcCtD
Procainamide—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000398	0.000941	CcSEcCtD
Procainamide—Pruritus—Methotrexate—urinary bladder cancer	0.000398	0.00094	CcSEcCtD
Procainamide—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000388	0.000916	CcSEcCtD
Procainamide—Urticaria—Doxorubicin—urinary bladder cancer	0.000387	0.000914	CcSEcCtD
Procainamide—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000385	0.000909	CcSEcCtD
Procainamide—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000385	0.000909	CcSEcCtD
Procainamide—Diarrhoea—Methotrexate—urinary bladder cancer	0.000385	0.000909	CcSEcCtD
Procainamide—Asthenia—Epirubicin—urinary bladder cancer	0.000378	0.000892	CcSEcCtD
Procainamide—Pruritus—Epirubicin—urinary bladder cancer	0.000372	0.000879	CcSEcCtD
Procainamide—Dizziness—Methotrexate—urinary bladder cancer	0.000372	0.000878	CcSEcCtD
Procainamide—Diarrhoea—Epirubicin—urinary bladder cancer	0.00036	0.000851	CcSEcCtD
Procainamide—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000359	0.000847	CcSEcCtD
Procainamide—Vomiting—Methotrexate—urinary bladder cancer	0.000358	0.000845	CcSEcCtD
Procainamide—Asthenia—Doxorubicin—urinary bladder cancer	0.000349	0.000825	CcSEcCtD
Procainamide—Dizziness—Epirubicin—urinary bladder cancer	0.000348	0.000822	CcSEcCtD
Procainamide—Pruritus—Doxorubicin—urinary bladder cancer	0.000345	0.000814	CcSEcCtD
Procainamide—Vomiting—Epirubicin—urinary bladder cancer	0.000335	0.00079	CcSEcCtD
Procainamide—Nausea—Methotrexate—urinary bladder cancer	0.000334	0.000789	CcSEcCtD
Procainamide—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000333	0.000787	CcSEcCtD
Procainamide—Dizziness—Doxorubicin—urinary bladder cancer	0.000322	0.000761	CcSEcCtD
Procainamide—Nausea—Epirubicin—urinary bladder cancer	0.000313	0.000738	CcSEcCtD
Procainamide—Vomiting—Doxorubicin—urinary bladder cancer	0.00031	0.000731	CcSEcCtD
Procainamide—Nausea—Doxorubicin—urinary bladder cancer	0.000289	0.000683	CcSEcCtD
Procainamide—DNMT1—Gene Expression—PPARG—urinary bladder cancer	0.000131	0.00055	CbGpPWpGaD
Procainamide—ACHE—Metabolism—TYMP—urinary bladder cancer	0.000131	0.00055	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PRSS3—urinary bladder cancer	0.00013	0.000548	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—SRC—urinary bladder cancer	0.00013	0.000547	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—SRC—urinary bladder cancer	0.00013	0.000547	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—RRM2—urinary bladder cancer	0.00013	0.000545	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—EP300—urinary bladder cancer	0.000129	0.000542	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—EP300—urinary bladder cancer	0.000129	0.000542	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	0.000128	0.000539	CbGpPWpGaD
Procainamide—SCN4A—Axon guidance—HRAS—urinary bladder cancer	0.000128	0.000539	CbGpPWpGaD
Procainamide—SCN2A—Axon guidance—HRAS—urinary bladder cancer	0.000128	0.000539	CbGpPWpGaD
Procainamide—DNMT1—Gene Expression—CREBBP—urinary bladder cancer	0.000126	0.000528	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000126	0.000528	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	0.000125	0.000527	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—SRC—urinary bladder cancer	0.000125	0.000527	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—SRC—urinary bladder cancer	0.000125	0.000527	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—SLC19A1—urinary bladder cancer	0.000125	0.000524	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—EGFR—urinary bladder cancer	0.000124	0.000521	CbGpPWpGaD
Procainamide—SCN10A—Axon guidance—HRAS—urinary bladder cancer	0.000124	0.00052	CbGpPWpGaD
Procainamide—SCN1A—Axon guidance—HRAS—urinary bladder cancer	0.000124	0.00052	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—SRC—urinary bladder cancer	0.000124	0.000519	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—HRAS—urinary bladder cancer	0.000123	0.000518	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PRSS3—urinary bladder cancer	0.000121	0.00051	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—RHOA—urinary bladder cancer	0.00012	0.000506	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—HPGDS—urinary bladder cancer	0.00012	0.000505	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—ENO2—urinary bladder cancer	0.00012	0.000505	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	0.000119	0.000502	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—EGFR—urinary bladder cancer	0.000119	0.000499	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	0.000119	0.000498	CbGpPWpGaD
Procainamide—ACHE—Metabolism—NAT2—urinary bladder cancer	0.000118	0.000497	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—TNF—urinary bladder cancer	0.000118	0.000497	CbGpPWpGaD
Procainamide—CHRM2—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000118	0.000494	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—KRAS—urinary bladder cancer	0.000117	0.000493	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000117	0.000492	CbGpPWpGaD
Procainamide—BCHE—Metabolism—TYMP—urinary bladder cancer	0.000117	0.00049	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—GSTT1—urinary bladder cancer	0.000116	0.00049	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—EGFR—urinary bladder cancer	0.000114	0.000479	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—EGFR—urinary bladder cancer	0.000114	0.000479	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—TNF—urinary bladder cancer	0.000113	0.000475	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—KRAS—urinary bladder cancer	0.000112	0.000471	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000112	0.000471	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—ERBB2—urinary bladder cancer	0.000111	0.000469	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—EGFR—urinary bladder cancer	0.00011	0.000462	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—EGFR—urinary bladder cancer	0.00011	0.000462	CbGpPWpGaD
Procainamide—SLC22A3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000109	0.000458	CbGpPWpGaD
Procainamide—SLC22A5—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000109	0.000457	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—TNF—urinary bladder cancer	0.000109	0.000456	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—TNF—urinary bladder cancer	0.000109	0.000456	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—EGFR—urinary bladder cancer	0.000108	0.000455	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—KRAS—urinary bladder cancer	0.000108	0.000453	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—KRAS—urinary bladder cancer	0.000108	0.000453	CbGpPWpGaD
Procainamide—BCHE—Metabolism—NAT2—urinary bladder cancer	0.000105	0.000443	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	0.000105	0.000443	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—TNF—urinary bladder cancer	0.000105	0.00044	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—TNF—urinary bladder cancer	0.000105	0.00044	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—TYMP—urinary bladder cancer	0.000104	0.000438	CbGpPWpGaD
Procainamide—CHRM2—Regulation of Actin Cytoskeleton—EGFR—urinary bladder cancer	0.000104	0.000437	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—KRAS—urinary bladder cancer	0.000104	0.000436	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—KRAS—urinary bladder cancer	0.000104	0.000436	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—KRAS—urinary bladder cancer	0.000102	0.00043	CbGpPWpGaD
Procainamide—ACHE—Metabolism—RRM2—urinary bladder cancer	0.000102	0.000429	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—HRAS—urinary bladder cancer	9.96e-05	0.000419	CbGpPWpGaD
Procainamide—CHRM2—G alpha (i) signalling events—CXCL8—urinary bladder cancer	9.88e-05	0.000415	CbGpPWpGaD
Procainamide—CHRM2—Regulation of Actin Cytoskeleton—KRAS—urinary bladder cancer	9.82e-05	0.000413	CbGpPWpGaD
Procainamide—ACHE—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	9.71e-05	0.000408	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—TYMP—urinary bladder cancer	9.71e-05	0.000408	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—NQO1—urinary bladder cancer	9.68e-05	0.000407	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—MMP9—urinary bladder cancer	9.56e-05	0.000402	CbGpPWpGaD
Procainamide—CHRM2—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	9.54e-05	0.000401	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—HRAS—urinary bladder cancer	9.53e-05	0.0004	CbGpPWpGaD
Procainamide—ACHE—Metabolism—ENO2—urinary bladder cancer	9.45e-05	0.000397	CbGpPWpGaD
Procainamide—ACHE—Metabolism—HPGDS—urinary bladder cancer	9.45e-05	0.000397	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—NAT2—urinary bladder cancer	9.42e-05	0.000396	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	9.39e-05	0.000395	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	9.33e-05	0.000392	CbGpPWpGaD
Procainamide—ACHE—Metabolism—GSTT1—urinary bladder cancer	9.17e-05	0.000385	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—HRAS—urinary bladder cancer	9.15e-05	0.000385	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—HRAS—urinary bladder cancer	9.15e-05	0.000385	CbGpPWpGaD
Procainamide—BCHE—Metabolism—RRM2—urinary bladder cancer	9.1e-05	0.000383	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—EP300—urinary bladder cancer	9.06e-05	0.000381	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	9.02e-05	0.000379	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HDAC4—urinary bladder cancer	8.86e-05	0.000372	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	8.85e-05	0.000372	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—NAT1—urinary bladder cancer	8.85e-05	0.000372	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—HRAS—urinary bladder cancer	8.82e-05	0.000371	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—HRAS—urinary bladder cancer	8.82e-05	0.000371	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—SRC—urinary bladder cancer	8.81e-05	0.000371	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—NAT2—urinary bladder cancer	8.78e-05	0.000369	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—HRAS—urinary bladder cancer	8.69e-05	0.000366	CbGpPWpGaD
Procainamide—BCHE—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	8.66e-05	0.000364	CbGpPWpGaD
Procainamide—BCHE—Metabolism—ENO2—urinary bladder cancer	8.43e-05	0.000354	CbGpPWpGaD
Procainamide—BCHE—Metabolism—HPGDS—urinary bladder cancer	8.43e-05	0.000354	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	8.38e-05	0.000352	CbGpPWpGaD
Procainamide—Lidocaine—EGFR—urinary bladder cancer	8.35e-05	1	CrCbGaD
Procainamide—BCHE—Metabolism—GSTT1—urinary bladder cancer	8.18e-05	0.000344	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—RRM2—urinary bladder cancer	8.13e-05	0.000342	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	8.09e-05	0.00034	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—GSTP1—urinary bladder cancer	8.07e-05	0.000339	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	8.05e-05	0.000338	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	7.85e-05	0.00033	CbGpPWpGaD
Procainamide—SLC22A2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	7.74e-05	0.000325	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—EGFR—urinary bladder cancer	7.73e-05	0.000325	CbGpPWpGaD
Procainamide—ACHE—Metabolism of proteins—IGF1—urinary bladder cancer	7.7e-05	0.000324	CbGpPWpGaD
Procainamide—ACHE—Metabolism—NQO1—urinary bladder cancer	7.62e-05	0.00032	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—RRM2—urinary bladder cancer	7.58e-05	0.000319	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—ENO2—urinary bladder cancer	7.53e-05	0.000317	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—HPGDS—urinary bladder cancer	7.53e-05	0.000317	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—TYMS—urinary bladder cancer	7.5e-05	0.000315	CbGpPWpGaD
Procainamide—DNMT1—Gene Expression—MYC—urinary bladder cancer	7.46e-05	0.000313	CbGpPWpGaD
Procainamide—ACHE—Neuronal System—HRAS—urinary bladder cancer	7.44e-05	0.000313	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—GLI1—urinary bladder cancer	7.42e-05	0.000312	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—GSTM1—urinary bladder cancer	7.42e-05	0.000312	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—NCOR1—urinary bladder cancer	7.42e-05	0.000312	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	7.39e-05	0.000311	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—TNF—urinary bladder cancer	7.36e-05	0.000309	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—GSTT1—urinary bladder cancer	7.3e-05	0.000307	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—KRAS—urinary bladder cancer	7.3e-05	0.000307	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	7.29e-05	0.000306	CbGpPWpGaD
Procainamide—SLC22A1—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	7.21e-05	0.000303	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—GPX1—urinary bladder cancer	7.1e-05	0.000299	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—ENO2—urinary bladder cancer	7.02e-05	0.000295	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—HPGDS—urinary bladder cancer	7.02e-05	0.000295	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—ERCC2—urinary bladder cancer	6.97e-05	0.000293	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	6.88e-05	0.000289	CbGpPWpGaD
Procainamide—BCHE—Metabolism of proteins—IGF1—urinary bladder cancer	6.87e-05	0.000289	CbGpPWpGaD
Procainamide—SLC22A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	6.84e-05	0.000287	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—GSTT1—urinary bladder cancer	6.81e-05	0.000286	CbGpPWpGaD
Procainamide—BCHE—Metabolism—NQO1—urinary bladder cancer	6.8e-05	0.000286	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	6.71e-05	0.000282	CbGpPWpGaD
Procainamide—BCHE—Neuronal System—HRAS—urinary bladder cancer	6.64e-05	0.000279	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.59e-05	0.000277	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—MTHFR—urinary bladder cancer	6.55e-05	0.000276	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.45e-05	0.000271	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	6.37e-05	0.000268	CbGpPWpGaD
Procainamide—ACHE—Metabolism—GSTP1—urinary bladder cancer	6.35e-05	0.000267	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—HRAS—urinary bladder cancer	6.2e-05	0.000261	CbGpPWpGaD
Procainamide—ACHE—Metabolism of proteins—CXCL8—urinary bladder cancer	6.19e-05	0.00026	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.15e-05	0.000258	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—NQO1—urinary bladder cancer	6.07e-05	0.000255	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—CXCL8—urinary bladder cancer	5.98e-05	0.000251	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—HRAS—urinary bladder cancer	5.93e-05	0.000249	CbGpPWpGaD
Procainamide—ACHE—Metabolism—TYMS—urinary bladder cancer	5.91e-05	0.000248	CbGpPWpGaD
Procainamide—ACHE—Metabolism—GSTM1—urinary bladder cancer	5.84e-05	0.000245	CbGpPWpGaD
Procainamide—ACHE—Metabolism—NCOR1—urinary bladder cancer	5.84e-05	0.000245	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.75e-05	0.000242	CbGpPWpGaD
Procainamide—BCHE—Metabolism—GSTP1—urinary bladder cancer	5.67e-05	0.000238	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—NQO1—urinary bladder cancer	5.66e-05	0.000238	CbGpPWpGaD
Procainamide—ACHE—Metabolism—GPX1—urinary bladder cancer	5.59e-05	0.000235	CbGpPWpGaD
Procainamide—BCHE—Metabolism of proteins—CXCL8—urinary bladder cancer	5.53e-05	0.000232	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—HRAS—urinary bladder cancer	5.52e-05	0.000232	CbGpPWpGaD
Procainamide—ACHE—Metabolism—ERCC2—urinary bladder cancer	5.49e-05	0.000231	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.48e-05	0.000231	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—TYMP—urinary bladder cancer	5.36e-05	0.000225	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PPARG—urinary bladder cancer	5.31e-05	0.000223	CbGpPWpGaD
Procainamide—BCHE—Metabolism—TYMS—urinary bladder cancer	5.27e-05	0.000222	CbGpPWpGaD
Procainamide—BCHE—Metabolism—NCOR1—urinary bladder cancer	5.21e-05	0.000219	CbGpPWpGaD
Procainamide—BCHE—Metabolism—GSTM1—urinary bladder cancer	5.21e-05	0.000219	CbGpPWpGaD
Procainamide—ACHE—Metabolism—MTHFR—urinary bladder cancer	5.16e-05	0.000217	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—CREBBP—urinary bladder cancer	5.11e-05	0.000215	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—RBX1—urinary bladder cancer	5.09e-05	0.000214	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—GSTP1—urinary bladder cancer	5.06e-05	0.000213	CbGpPWpGaD
Procainamide—BCHE—Metabolism—GPX1—urinary bladder cancer	4.99e-05	0.00021	CbGpPWpGaD
Procainamide—BCHE—Metabolism—ERCC2—urinary bladder cancer	4.9e-05	0.000206	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—NAT2—urinary bladder cancer	4.85e-05	0.000204	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TSC1—urinary bladder cancer	4.78e-05	0.000201	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—GSTP1—urinary bladder cancer	4.72e-05	0.000198	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—TYMS—urinary bladder cancer	4.71e-05	0.000198	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—NCOR1—urinary bladder cancer	4.65e-05	0.000196	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—GSTM1—urinary bladder cancer	4.65e-05	0.000196	CbGpPWpGaD
Procainamide—BCHE—Metabolism—MTHFR—urinary bladder cancer	4.6e-05	0.000194	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—JAG1—urinary bladder cancer	4.55e-05	0.000191	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—GPX1—urinary bladder cancer	4.45e-05	0.000187	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—TYMS—urinary bladder cancer	4.39e-05	0.000184	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—ERCC2—urinary bladder cancer	4.37e-05	0.000184	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—GSTM1—urinary bladder cancer	4.34e-05	0.000182	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—NCOR1—urinary bladder cancer	4.34e-05	0.000182	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—RRM2—urinary bladder cancer	4.19e-05	0.000176	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PPARG—urinary bladder cancer	4.18e-05	0.000176	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PTGS2—urinary bladder cancer	4.18e-05	0.000176	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—GPX1—urinary bladder cancer	4.15e-05	0.000175	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—MTHFR—urinary bladder cancer	4.11e-05	0.000173	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—ERCC2—urinary bladder cancer	4.08e-05	0.000171	CbGpPWpGaD
Procainamide—ACHE—Metabolism—CREBBP—urinary bladder cancer	4.02e-05	0.000169	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	3.88e-05	0.000163	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ENO2—urinary bladder cancer	3.88e-05	0.000163	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—RHOA—urinary bladder cancer	3.85e-05	0.000162	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—MTHFR—urinary bladder cancer	3.83e-05	0.000161	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	3.76e-05	0.000158	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PPARG—urinary bladder cancer	3.73e-05	0.000157	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—S100B—urinary bladder cancer	3.69e-05	0.000155	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PTEN—urinary bladder cancer	3.65e-05	0.000153	CbGpPWpGaD
Procainamide—BCHE—Metabolism—CREBBP—urinary bladder cancer	3.59e-05	0.000151	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—RHOA—urinary bladder cancer	3.5e-05	0.000147	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—EP300—urinary bladder cancer	3.48e-05	0.000146	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.38e-05	0.000142	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PPARG—urinary bladder cancer	3.33e-05	0.00014	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NCOR1—urinary bladder cancer	3.32e-05	0.000139	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PTGS2—urinary bladder cancer	3.29e-05	0.000138	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—IL2—urinary bladder cancer	3.23e-05	0.000136	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—CREBBP—urinary bladder cancer	3.2e-05	0.000135	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—NQO1—urinary bladder cancer	3.12e-05	0.000131	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PPARG—urinary bladder cancer	3.11e-05	0.000131	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—CXCL8—urinary bladder cancer	3.07e-05	0.000129	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—CREBBP—urinary bladder cancer	2.98e-05	0.000125	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PTGS2—urinary bladder cancer	2.94e-05	0.000123	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—IL2—urinary bladder cancer	2.93e-05	0.000123	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TERT—urinary bladder cancer	2.92e-05	0.000123	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PTEN—urinary bladder cancer	2.87e-05	0.000121	CbGpPWpGaD
Procainamide—ACHE—Metabolism—EP300—urinary bladder cancer	2.74e-05	0.000115	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—FGFR3—urinary bladder cancer	2.68e-05	0.000113	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PTGS2—urinary bladder cancer	2.62e-05	0.00011	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	2.61e-05	0.00011	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—ESR1—urinary bladder cancer	2.6e-05	0.00011	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PTEN—urinary bladder cancer	2.56e-05	0.000108	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PTGS2—urinary bladder cancer	2.44e-05	0.000103	CbGpPWpGaD
Procainamide—BCHE—Metabolism—EP300—urinary bladder cancer	2.44e-05	0.000103	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—TYMS—urinary bladder cancer	2.42e-05	0.000102	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	2.39e-05	0.000101	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	2.39e-05	0.000101	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GPX1—urinary bladder cancer	2.29e-05	9.64e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PTEN—urinary bladder cancer	2.29e-05	9.61e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CREBBP—urinary bladder cancer	2.28e-05	9.6e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—IGF1—urinary bladder cancer	2.25e-05	9.48e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	2.25e-05	9.47e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—EGFR—urinary bladder cancer	2.24e-05	9.43e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—EP300—urinary bladder cancer	2.18e-05	9.17e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PTEN—urinary bladder cancer	2.13e-05	8.96e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—KRAS—urinary bladder cancer	2.12e-05	8.91e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	2.12e-05	8.9e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—RHOA—urinary bladder cancer	2.07e-05	8.68e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—EP300—urinary bladder cancer	2.03e-05	8.55e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—ERBB2—urinary bladder cancer	1.91e-05	8.04e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CXCL8—urinary bladder cancer	1.81e-05	7.62e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—HRAS—urinary bladder cancer	1.8e-05	7.57e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—IL2—urinary bladder cancer	1.73e-05	7.29e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.72e-05	7.21e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CCND1—urinary bladder cancer	1.69e-05	7.1e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.65e-05	6.93e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MMP9—urinary bladder cancer	1.64e-05	6.89e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.63e-05	6.87e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PTEN—urinary bladder cancer	1.63e-05	6.85e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—EP300—urinary bladder cancer	1.55e-05	6.54e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SRC—urinary bladder cancer	1.51e-05	6.36e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MYC—urinary bladder cancer	1.35e-05	5.7e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.35e-05	5.68e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—EGFR—urinary bladder cancer	1.33e-05	5.57e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—KRAS—urinary bladder cancer	1.25e-05	5.26e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.18e-05	4.95e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.12e-05	4.72e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TP53—urinary bladder cancer	1.11e-05	4.68e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HRAS—urinary bladder cancer	1.06e-05	4.47e-05	CbGpPWpGaD
